ImClone Systems Inc. watched its shares drop Thursday following news that the company is nixing its plans for a merger, partnership or outright sale in favor of continuing on alone. (BioWorld Today)
As a complement to its lead cardiovascular drug, MC-1, Medicure Inc. acquired rights to its first marketed product, Aggrastat, a glycoprotein IIb/IIIa inhibitor to treat acute coronary syndrome. (BioWorld Today)
Inspire Pharmaceuticals Inc. may have hit the end of the road for a Phase II product designed for use in cardiopulmonary bypass procedures. (BioWorld Today)
A Conforma Therapeutics Corp. spinout, barely three months old, closed a $27.5 million Series A financing to cover Phase II trials of its only product, Calsed, to treat small-cell lung cancer. (BioWorld Today)
Shares of Icagen Inc. plunged 73.6 percent Friday following news that an independent Data Monitoring Committee recommended the company stop treating half the patients in a Phase III trial of ICA-17043 for sickle cell disease. (BioWorld Today)
Privately held BioNumerik Pharmaceuticals Inc. learned that its lead neuropathy candidate failed to hit the primary endpoints in two Phase III studies, threatening the status of its North American partnership less than two months after the company withdrew an initial public offering. (BioWorld Today)
A company formed in January 2002, based on research conducted at the Brookhaven National Laboratory, filed for an initial public offering to raise $40.25 million - money to support clinical development of its only product, a GABA analog to treat cocaine addiction. (BioWorld Today)
